To evaluate whether intravenous Adenosine would replace the need for inhaled nitric oxide (iNO) in the management of Persistent Pulmonary Hypertension of the Newborn (PPHN)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51768118

Enrollment

Registered

2004-09-30

Start date

2002-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Diseases: Persistant pulmonary hypertension Neonatal Diseases Other pulmonary heart diseases

Interventions

1. Intravenous adenosine 2. No adenosine

Eligibility

Inclusion criteria

Inclusion criteria: Neonates with PPHN requiring mechanical ventilation and inhaled nitric oxide at 20 parts per million

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Whether Adenosine can replace or supplement the use of iNO in the treatment of PPHN.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026